After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with a ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

近日，国家卫生健康委员会主任宣布将持续推进“ 体重管理年”行动，鼓励医疗机构设立体重门诊，采用多学科干预手段帮助患者减重。这一举措无疑为减重市场注入了强大的动力，也预示着肥胖治疗领域即将迎来一场前所未有的变革。

announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity usin An update from Ibio ( (IBIO ...

Merck , known as MSD outside of the United States and Canada, today announced that new clinical and outcomes research data will be presented at the American College of Cardiology's Annual Scientific ...

After hours: March 18 at 6:45:25 PM EDT Loading Chart for IBIO ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

After hours: March 14 at 6:24:46 p.m. EDT Loading Chart for IBIO ...